Baudax Bio (BXRX) Stock News, May 1-5, 2020

Baudax Bio (NASDAQ:BXRX) announced a virtual presentation of ANJESO™ (meloxicam) injection data at Digestive Disease Week (DDW) 2020. The findings show significant reductions in opioid use and hospital stay length by approximately one day when administered preoperatively for colorectal surgeries. Costs remained similar to placebo groups. ANJESO, approved by the FDA in February 2020, is expected to launch commercially by June 2020, addressing opioid-related issues with its non-addictive profile and analgesic effects.